GlycoVaxyn Injected with $9.3M

GlycoVaxyn, a Swiss developer of innovative conjugated vaccines, has raised a $9.3 million in a Series A financing. Existing investors Sofinnova Partners and Index Ventures both significantly increased their equal investment in GlycoVaxyn, after having seeded the company in July 2006. Also, GlycoVaxyn has appointed industry veteran Michel Greco as chairman of the board.